

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/743,384	12/23/2003	Richard Eric Rothman	001107.000412 7753	
22907 7590 01/30/2007 BANNER & WITCOFF 1001 G STREET N W SUITE 1100 WASHINGTON, DC 20001			EXAMINER	
			WILDER, CYNTHIA B	
			ART UNIT	PAPER NUMBER
	.,		1637	
SHORTENED STATUTORY PERIOD OF RESPONSE		MAIL DATE	DELIVERY MODE	
3 MONTHS		01/30/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

	Application No.	Applicant(s)	
	10/743,384	ROTHMAN ET AL.	
Office Action Summary	Examiner	Art Unit	
	Cynthia B. Wilder, Ph.D.	1637	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet with the	correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 36(a). In no event, however, may a reply be ting will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. mely filed the mailing date of this communication. ED (35 U.S.C. § 133).	
Status			
 1) ⊠ Responsive to communication(s) filed on 14 No. 2a) ☐ This action is FINAL. 2b) ☒ This 3) ☐ Since this application is in condition for allowant closed in accordance with the practice under E 	action is non-final.		
Disposition of Claims			
 4) Claim(s) 1-42 is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) Claim(s) is/are allowed. 6) Claim(s) 1-42 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or 	vn from consideration.		
Application Papers			
9) The specification is objected to by the Examiner 10) The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the or Replacement drawing sheet(s) including the correction 11) The oath or declaration is objected to by the Examiner	epted or b) objected to by the drawing(s) be held in abeyance. Se ion is required if the drawing(s) is ot	ne 37 CFR 1.85(a). Dijected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
 12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priori application from the International Bureau * See the attached detailed Office action for a list of 	s have been received. s have been received in Applicat ity documents have been receiv ı (PCT Rule 17.2(a)).	ion No ed in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal I 6) Other:	Pate	

Application/Control Number: 10/743,384

Art Unit: 1637

DETAILED ACTION

Page 2

1. Applicant's amendment filed 11/14/2006 is acknowledged and has been entered. Claims

1, 4, 5, 6, 16, 19, 20, 21 have been amended. Claims 43-52 have been canceled. Claims 1-42 are

pending. All of the amendments and arguments have been thoroughly reviewed and considered

but are not found persuasive for the reasons discussed below. Any rejection not reiterated in this

action has been withdrawn as being obviated by the amendment of the claims.

This action is made FINAL.

2. The text of those sections of Title 35, U.S. Code not included in this action can be found

in a prior Office action.

Previous Objections and Rejections

3. The objection to the specification is withdrawn in view of Applicant's amendment. The

new matter rejection under 35 USC 112 first paragraph is withdrawn in view of Applicant's

amendment to the claims. The claim rejection under 35 USC 112 second paragraph is

maintained and discussed below.

Claim Rejections - 35 USC § 112 second paragraph

4. Once again claims 1-42 are rejected under 35 U.S.C. 112, second paragraph, as being

indefinite for failing to particularly point out and distinctly claim the subject matter which

applicant regards as the invention.

(a) Claims 1-42 are confusing in claims 1 and 16 for the limitation:

"wherein the primers when in the presence of a S. aureus 16S rRNA gene amplify a segment of the gene comprising a conserved region and a first divergent region, wherein the conserved region comprises at least

18 contiguous nucleotides which are at least 80% identical among at least 10 eubacterial species wherein

the first divergent region comprises at least 10 contiguous nucleotides and differs by at least 3 nucleotides from a second divergent region found in Bradyrhizobium japonicum 16S rRNA gene",

because it is unclear as to what "segment" of the *S. aureus* 16S rRNA gene the primers is actually amplifying or how amplifying theses segments relate to determining species source of eubacterial DNA. It appears that Applicant has described properties of the *S. aureus* 16S rRNA gene, but the nexus between these properties as it relates to the divergent region of Bradyrhizobium Japonicum and the step of amplifying a segment of S. aureus 16S rRNA gene with primers is unclear. It appears that the primer can amplify any segment of the S. aureus 16S RNA gene. Likewise, if *S. aureus* is not present, does the method still operate or is *S. aureus* a requirement for the method? How this relates to determining a first species of eubacterial in a sample is ambiguous and unclear. Clarification is required.

Applicants' Traversal

Applicant traverses the rejection on the following ground: Applicant states that in the presence of a template from *S. aureus* 16S rRNA gene the primer amplify a segment that comprises a conserved region and a divergent region. Applicant states that the conserved region and the divergent region are defined by similarities to at least 10 eubacterial species (conserved) or divergence from *Bradyrhizobium* (divergent), respectively, *S. aureus* 16S rRNA gene contains more than one such segment, but not any segment of the gene will fulfill these criteria. Applicant states that an example of one such segment is recited in claim 3, nucleotides 890-1051. Applicant states that the method of the present claims does not recite or specify the amplifying of a segment of *S. aureus* 16S rRNA gene. Applicant states that the ability to amplify *S. aureus* 16S rRNA gene is a property of the primes. Applicant states that the recited step of amplifying

Page 4

template DNA is from *S. aureus*. Applicant states that the template DNA which amplified can be from any eubacteria. Applicant states that in fact, the purpose of the method is detect and determine species of a eubacterial (which may be unidentified at the outset of the assay) by virtue of detecting an amplifying its rRNA.

Examiner's response

All of the arguments have been thoroughly reviewed and considered but are not found 6. persuasive for the reasons that follow: In response to Applicant's arguments, the Examiner maintains that the claims are confusing overall because a clear nexus between the steps is unclear. Specifically, it is unclear how the claim method operates to detect and determine species source of eubacterial DNA in a sample. Firstly, it is confusing the relevance of the S. aureus 16S rRNA because the claims recited that "the primer when in the presence of a S. aureus 16S rRNA gene amplify a segment of the gene. If the primers are not in the presence of S. aureus does the method still operate or is S. aureus a requirement for determining various eubacterial DNA species? Secondly, it is unclear which segments of the S. aureus gene the primers amplify. The examiner maintains that the limitation "wherein the primer when in the presence of a S. aureus 16S rRNA gene amplify a segment of the gene comprising a conserved region and a first divergent region..." appears to be a property of the S. aureus gene and does not provide any characteristics of the segments or limit the segment being amplified by the primers. Therefore, it appears that any segment of the primer can be amplified by the primers irregardless to whether or not it is in a conserved region of the S. aureus gene. Thirdly, since it is unclear what is being

Application/Control Number: 10/743,384

Art Unit: 1637

amplified by the primers, the nexus between the presence or absence of *S. aureus* and the hybridization of probes to divergent regions of *Bradyrhizobium Japonicum* is unclear.

Conclusion

7. No claims are allowed. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Cynthia B. Wilder, Ph.D. whose telephone number is (571) 272-0791. The examiner can normally be reached on a flexible schedule.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/743,384

Art Unit: 1637

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

cbw

ADV PENTION PH.D

Page 6

IPERV XAMINEI

TECHNOLOGY CENTER 1600